Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/8285
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Selective inhibition of yeast regulons by daunorubicin: A transcriptome-wide analysis |
Autor: | Rojas, Marta CSIC; Casado, Marta CSIC ORCID ; Portugal, José CSIC ORCID ; Piña, Benjamín CSIC ORCID | Palabras clave: | Daunorubicin Selective inhibition Yeast transcriptome |
Fecha de publicación: | 30-jul-2008 | Editor: | BioMed Central | Citación: | BMC Genomics 9 (358): 2008 | Resumen: | Background The antitumor drug daunorubicin exerts some of its cytotoxic effects by binding to DNA and inhibiting the transcription of different genes. We analysed this effect in vivo at the transcriptome level using the budding yeast Saccharomyces cerevisiae as a model and sublethal (IC40) concentrations of the drug to minimise general toxic effects. Results Daunorubicin affected a minor proportion (14%) of the yeast transcriptome, increasing the expression of 195 genes and reducing expression of 280 genes. Daunorubicin down-regulated genes included essentially all genes involved in the glycolytic pathway, the tricarboxylic acid cycle and alcohol metabolism, whereas transcription of ribosomal protein genes was not affected or even slightly increased. This pattern is consistent with a specific inhibition of glucose usage in treated cells, with only minor effects on proliferation or other basic cell functions. Analysis of promoters of down-regulated genes showed that they belong to a limited number of transcriptional regulatory units (regulons). Consistently, data mining showed that daunorubicin-induced changes in expression patterns were similar to those observed in yeast strains deleted for some transcription factors functionally related to the glycolysis and/or the cAMP regulatory pathway, which appeared to be particularly sensitive to daunorubicin. Conclusion The effects of daunorubicin treatment on the yeast transcriptome are consistent with a model in which this drug impairs binding of different transcription factors by competing for their DNA binding sequences, therefore limiting their effectiveness and affecting the corresponding regulatory networks. This proposed mechanism might have broad therapeutic implications against cancer cells growing under hypoxic conditions. | Descripción: | 16 páginas, 6 figuras, 9 tablas. | Versión del editor: | http://dx.doi.org/10.1186/1471-2164-9-358 | URI: | http://hdl.handle.net/10261/8285 | DOI: | 10.1186/1471-2164-9-358 | ISSN: | 1471.2164 |
Aparece en las colecciones: | (IBMB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
1471-2164-9-358.pdf | 1,01 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
4
checked on 17-abr-2024
SCOPUSTM
Citations
11
checked on 16-abr-2024
WEB OF SCIENCETM
Citations
12
checked on 25-feb-2024
Page view(s)
426
checked on 23-abr-2024
Download(s)
243
checked on 23-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.